List/Grid
Miltenyi Biomedicine stellt die Primäranalyse der zulassungsrelevanten DALY-2-EU-Studie zur Zweitlinientherapie des rezidivierten/refraktären großzelligen B-Zell-Lymphoms auf der 67. Jahrestagung der American Society of Hematology (ASH) vor
Die Ergebnisse der DALY 2–EU–Studie zeigen, dass Zamtocabtagen Autoleucel (Zamto–cel) bei Patienten mit rezidiviertem/refraktärem großzelligem B–Zell–Lymphom (r/r LBCL) eine klinisch bedeutsame Überlegenheit ...
À l’occasion de la 67e réunion annuelle de l’American Society of Hematology (ASH), Miltenyi Biomedicine présente l’analyse primaire de l’essai pivot DALY 2-EU pour le traitement de seconde ligne du lymphome à grandes cellules B en rechute ou réfractaire
Les résultats de l’essai DALY 2–EU révèlent que le zamtocabtagene autoleucel (zamto–cel) présente une supériorité cliniquement significative par rapport à la chimio–immunothérapie ...
Miltenyi Biomedicine divulga análise primária do estudo principal do DALY 2-EU para linfoma de células B grandes recidivante/refratário de segunda linha na 67ª Reunião Anual da Sociedade Americana de Hematologia (ASH)
Os resultados do DALY 2–UE mostram que o autoleucel de zamtocabtageno (zamto–cel) demonstrou superioridade clinicamente significativa em relação à quimioimunoterapia em pacientes com linfoma de células B grandes ...
Cochin Shipyard to build next-generation electric TRAnsverse tugs for Svitzer
Cochin, India and Copenhagen, Denmark – 8 December 2025. Svitzer, a leading global towage provider, and Cochin Shipyard Limited (CSL), India’s largest public sector shipyard, have signed a shipbuilding agreement for four 26–metre electric ...
Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting
DALY 2–EU results show zamtocabtagene autoleucel (zamto–cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B–cell lymphoma (r/r LBCL)1
Zamto–cel was well–tolerated ...
A Moonup Technology firma parceria com a Shelly, líder europeia em casas inteligentes, para apresentar um ecossistema completo de edifícios inteligentes na Taipei Building Show de 2025
TAIPEI, Taiwan, Dec. 06, 2025 (GLOBE NEWSWIRE) — A Moonup Technology Co., Ltd., parceira de operações em Taiwan da Shelly (Shelly Group), líder europeia em casas inteligentes, anunciou sua participação de destaque ...
Moonup Technology geht Partnerschaft mit dem europäischen Smart-Home-Marktführer Shelly ein, um auf der Taipei Building Show 2025 ein umfassendes Smart-Building-Ökosystem zu präsentieren
TAIPEI, Taiwan, Dec. 06, 2025 (GLOBE NEWSWIRE) — Moonup Technology Co., Ltd., der taiwanesische Partner des europäischen Smart–Home–Marktführers Shelly (Shelly Group), gab seine bedeutende Teilnahme an der Taipei Building ...
Moonup Technology s’associe à Shelly, le leader européen de la maison intelligente, pour présenter un écosystème complet de bâtiments intelligents au Taipei Building Show 2025
TAIPEI, Taïwan, 06 déc. 2025 (GLOBE NEWSWIRE) — Moonup Technology Co., Ltd., partenaire opérationnel taïwanais du leader européen de la maison intelligente Shelly (Shelly Group), a annoncé sa participation majeure ...
MRX DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Marex Group plc Investors with Losses in Excess of $100K to Secure Counsel Before Important December 8 Deadline in Securities Class Action – MRX
NEW YORK, Dec. 06, 2025 (GLOBE NEWSWIRE) —
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Marex Group plc (NASDAQ: MRX) between May 16, 2024 and August 5, 2025, both dates inclusive (the “Class ...
MLTX IMPORTANT DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages MoonLake Immunotherapeutics Investors with Losses in Excess of $100K to Secure Counsel Before Important December 15 Deadline in Securities Class Action – MLTX
NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) —
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive ...
